Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4929097 in Recurrent or Refractory NSCLC
NCT01070927Phase 2Completed
- Sponsor
- Roche
- Start
- Jan 2010
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of RO4929097 in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Roche. Primary endpoints: Tumour blood flow at Day 16 and Tumour metabolic response rate at Day 16. Started Jan 2010; status: completed.
02
Drugs
RO4929097
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01070927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01070927.